数据
资源
版本对比
免费注册
预约演示
免费注册
Salix Pharmaceuticals
Culminates Year-Long
Constipation
Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
2022-12-01
·
BioSpace
Launching in December for
Constipation
Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023 LAVAL, QC / ACCESSWIRE / December 1, 2022 /
Salix Pharmaceuticals, Ltd.
("Salix"), the gastroenterology business of
Bausch Health Companies Inc.
(NYSE:BHC)(TSX:BHC) ("Bausch Health"), today announced the launch of a series of social media and digital initiatives to raise awareness during
Constipation
Awareness Month in December. The initiatives will discuss
constipation diseases
, including
opioid-induced constipation (OIC)
,
irritable bowel syndrome
with
constipation (IBS-C)
and
chronic idiopathic constipation (CIC)
. It is estimated that approximately up to 80% of patients receiving opioid medications for
chronic pain
experience
OIC,1
30 million adults have CIC,2,3 and 3.4 million have IBS-C.2,3 The initiatives launching this month culminate a year in which Salix invested in a multipronged educational campaign that included the publication of digital content reaching more than 240 million consumers with valuable information about the symptoms of
OIC
,
IBS-C
, and CIC and treatment options they can discuss with their health care providers.
Constipation
Awareness Month initiatives included partnerships with Johanna Grange, a lifestyle influencer who is sharing her perspectives about living with
IBS-C
with her 73,000 Instagram followers and in her blog, and Ethan Melillo, a pharmacist with more than 189,000 TikTok followers, who over the past year has been working with Salix to share a series of informative videos on TikTok discussing
OIC
and treatment options. "As an industry leader in the gastroenterology space, Salix is continually identifying innovative ways to connect with the patient communities we serve," said Nicola Kayel, vice president, Gastroenterology Marketing, Salix. "In 2022, in addition to continuing to work with social media influencers lending their voice to raise awareness of
gastrointestinal (GI) diseases
, Salix became the first organization to partner with the creators of the PLOP app, a new and creative bowel movement tracker digital solution that monitors and analyzes daily symptoms. The collaboration, which raises awareness about the connection between opioid pain medications and
constipation
, supports valuable conversations between patients and health care providers that may help lead to improved regularity in bowel movements." To further support patients with
chronic GI disorders
in 2023, Salix will extend its partnerships with prestigious patient advocacy groups to advance public awareness and education for patients and health care providers. Salix will continue its collaboration with the International Foundation for
Gastrointestinal Disorders
(IFFGD), the U.S.
Pain
Foundation, the American
Chronic Pain
Association (ACPA), and the
American College of Emergency Physicians
(ACEP). Through its 2023 medical grant contributions program, Salix will continue to work with organizations such as the American Gastroenterological Association (AGA) to advance research that will improve understanding of GI conditions. Salix will continue to host patient resources at UnderstandingOIC.com and ConfrontConstipation.com which also offer information about treatment options to be discussed with health care providers. About
Salix
Salix Pharmaceuticals
is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of
gastrointestinal diseases
. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology,
pain
specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit and connect with us on Twitter and LinkedIn. About
Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in
Bausch + Lomb
. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn. Forward-looking Statements This news release may contain forward-looking statements about the future performance of Bausch Health including the proposed plan to fully separate its eye health business, including the timing thereof, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to
Bausch Health
's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. ### ©2022
Salix Pharmaceuticals
or its affiliates. SAL.0120.USA.22 1 Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of
opioid-induced bowel dysfunction
: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35-42. doi:10.1111/j.1526-4637.2008.00495.x 2 Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of
Functional Gastrointestinal Disorders
, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014 3 Bureau USC. National Demographic Analysis Tables: 2020. Census.gov. . Published March 10, 2022. Accessed November 22, 2022. Investor Contact: Christina Cheng ir@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com (908) 541-3785 Gianna Scalera salixcommunications@bauschhealth.com (908) 541-2110 SOURCE:
Salix Pharmaceuticals
View source version on accesswire.com:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Salix Pharmaceuticals, Inc.
American College of Emergency Physicians
Bausch Health Cos., Inc.
[+2]
适应症
便秘
阿片类药物引起的便秘
肠易激综合征
[+7]
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务